Back icon Back Share
Freenome

Freenome

Company

By Sriparna Roy
Feb 15 (Reuters) – Blood test developer Freenome said on Thursday it has raised $254 million in a new funding round led by Swiss drugmaker Roche, to develop tests that can potentially detect multiple early-stage cancers. The company did not disclose the valuation at which the funds were raised.

https://www.reuters.com/business/healthcare-pharmaceuticals/cancer-test-firm-freenome-raises-254-mln-fresh-funding-2024-02-15/

Specification

Date

Feb 15, 2024

Category

healthcare

Lead investor

Country Icon Roche Venture Fund

Stage

Series E

Size

$254M

Location

Explore similar Investments to Freenome

Company
Size
Date
Lead Investor
Press
The Network

The Network

Company
$2.5M
Aug 6, 2025
Investor HF0
Source
Harmonic

Harmonic

Company
$100M
Jul 10, 2025
Investor Kleiner Perkins
Source
Moderne

Moderne

Company
$30M
Feb 11, 2025
Investor Acrew Capital
Source
PhysicsX

PhysicsX

Company
$135M
Jun 25, 2025
Investor Atomico
Source
FLORA

FLORA

Company
$6.5M
May 28, 2025
Investor Hanabi Capital
Source
Tavily

Tavily

Company
$20M
Aug 6, 2025
Investor Insight Partners
Source
Savvy Wealth

Savvy Wealth

Company
$72M
Jul 2, 2025
Investor Industry Ventures
Source
Kaedim

Kaedim

Company
$15M
Mar 11, 2024
Investor a16z
Source
Ambrook

Ambrook

Company
$26.1M
Jul 1, 2025
Investor Thrive Capital
Source
Supabase

Supabase

Company
$200M
Apr 22, 2025
Investor Accel
Source
PostHog

PostHog

Company
$70M
Jun 9, 2025
Investor Stripe
Source
ORO

ORO

Company
$6M
Apr 16, 2025
Investor a16z
Source